At a glance

What is BPC-157?

BPC-157, short for “Body Protection Compound-157,” is a synthetic pentadecapeptide¹, a chain of 15 amino acids (sequence GEPPPGKPADDAGLV). It is a lab-made fragment modeled on a larger protective protein that occurs naturally in human gastric juice, the acidic fluid the stomach uses to break down food.

Unlike a hormone such as insulin, BPC-157 does not appear to act on a single, well-defined receptor. Researchers instead describe it as a “cytoprotective” agent², meaning a molecule associated with protecting and maintaining the integrity of cells and tissue in laboratory and animal models.

BPC-157 has never been approved as a medicine through the FDA.

The history of BPC-157

The idea behind BPC-157 dates to 1975, when a Croatian medical student named Predrag Sikiric attended a lecture on the body’s stress response at the University of Zagreb. He reasoned that if stress can damage the stomach, the stomach might also produce its own protective substance.

By 1983, Sikiric had assembled a team that collected human and animal gastric juice from hospitals, emergency rooms, and slaughterhouses to search for the active ingredient. In 1989, the group isolated a 15 amino acid peptide called BPC-157. The name and number carried personal and patriotic meaning for Sikiric during a turbulent period in Croatia’s history, as described in a 2026 STAT News profile³ of the researcher.

From 1993, the Zagreb pharmaceutical company PLIVA, later working with Parke-Davis, developed the peptide and ran early animal studies along with two small human trials for ulcerative colitis in the early 2000s. The second of those trials reported a positive effect that did not reach statistical significance. After GlaxoSmithKline acquired PLIVA’s research institute in 2006, the program was shelved, and the rights returned to Sikiric in 2009.

Without a pharmaceutical company continuing its development, BPC-157 followed an unusual path. Around 2010, it spread through online forums and Sikiric’s published papers, and suppliers began selling it directly. It has circulated as a research chemical ever since. Most of the underlying studies still come from Sikiric’s own laboratory. A 2025 systematic review⁴ identified 544 BPC-157 articles published between 1993 and 2024, most of them from a small number of research groups.

The only registered interventional human trial of BPC-157 was a small Phase I safety study of oral tablets (NCT02637284⁵) run in Tijuana, Mexico around 2015 and 2016. It was never completed to publication and remains listed with an “unknown” status and no posted results, so even its basic safety findings in humans were never independently reported.

How does BPC-157 work?

The proposed mechanisms come almost entirely from animal and cell studies. The most consistent finding is that BPC-157 promotes angiogenesis², the growth of new blood vessels, mainly through the VEGFR2-Akt-eNOS pathway and by influencing the nitric oxide system, which helps regulate blood flow and vascular health.

In laboratory models, researchers have also reported that BPC-157 increases collagen production, activates fibroblasts, reduces inflammatory signaling, and affects pain pathways¹. In tendon cells, it has been shown to increase expression of the growth hormone receptor. Across rodent studies, it has been associated with faster healing of muscle, tendon, ligament, bone, and gastrointestinal tissue.

In animal data, BPC-157 is metabolized in the liver, cleared by the kidneys, and has a short half-life of under 30 minutes⁴. None of these findings have been confirmed in controlled human studies.

Is BPC-157 FDA-approved?

No, BPC-157 has never been approved by the FDA, or any comparable regulator, for any condition, and it has not completed the controlled human trials that approval requires.

Its regulatory status has also changed several times:

• 2023: The FDA placed BPC-157 in Category 2 of its interim 503A bulk drug substances list⁶, the category for substances that may present significant safety risks, which restricted compounding pharmacies from making it.
• April 2026: The FDA removed BPC-157 from that category because the nominators withdrew their nominations⁷. BPC-157 is still not on the 503A bulks list or in Category 1.
• July 23, 2026: Its Pharmacy Compounding Advisory Committee voted in favor⁸ of allowing the peptide to be compounded, meaning prepared for individual patients by licensed compounding pharmacies rather than mass-produced and sold as a standardized, FDA-approved drug.

That vote is a recommendation only. The FDA still has to write and finalize a rule, so BPC-157 is not currently cleared for compounding and remains unapproved. Being permitted for compounding would also not be the same as FDA approval.

BPC-157 is also prohibited at all times in sport⁹ under the World Anti-Doping Agency’s S0 category for non-approved substances.

What does the research show?

The research on BPC-157 is overwhelmingly preclinical. The 2025 systematic review in orthopedic sports medicine screened the literature and included 36 studies, of which 35 were preclinical (animal or laboratory) and only one involved humans⁴. There are no completed randomized controlled human trials, and there is no long-term human data.

A 2019 review¹⁰ reached a similar conclusion, describing consistent healing effects in rodents while noting that efficacy is “yet to be confirmed in humans.” The animal research is broad and fairly consistent, but the human research needed to draw firm conclusions has not been done.

The most replicated animal findings involve tendons. In rats with a cut Achilles tendon, BPC-157 improved tendon strength, elasticity, and function¹¹ and shrank the defect by day 14.

The one human report is a retrospective, uncontrolled series of 12 patients with chronic knee pain. After a single knee injection, seven of them (58%) reported relief lasting more than 6 months⁴. The report published no effect size or safety data.

What is the difference between BPC-157 and TB-500?

BPC-157 is often mentioned alongside TB-500, a synthetic fragment of the protein thymosin beta-4. The two share several features. Both are peptides, unapproved by the FDA, prohibited in sports, and have been studied mainly in animals rather than in humans.

The differences are largely mechanistic:

Neither has controlled human evidence.

Frequently asked questions

Is BPC-157 FDA-approved?

No. BPC-157 is not FDA-approved for any indication. As of September 2026, it is not eligible for 503A compounding: FDA removed it from Category 2 in April 2026 after the nomination was withdrawn, but it is not on the 503A bulks list or in Category 1, so licensed compounding pharmacies in the United States still cannot legally use it.

Is BPC-157 legal in the United States?

BPC-157 cannot be legally compounded or dispensed by a licensed pharmacy in the United States because it is not on the 503A bulks list or in Category 1, even after FDA removed it from Category 2 in April 2026. Products sold as BPC-157 for human use through online vendors or research chemical suppliers operate outside the regulated pharmaceutical system. Obtaining and using an unregulated compound with no pharmaceutical oversight carries both legal and safety risks.

Can BPC-157 be prescribed by a doctor?

No. Because BPC-157 is not on the 503A bulks list or in Category 1, licensed compounding pharmacies cannot compound it for patient use. A physician cannot legally prescribe a compound that a licensed pharmacy cannot dispense. Any product a prescriber attempts to order through regulated channels would not be fillable.

What is BPC-157 used for in research?

BPC-157 has been studied in preclinical (animal) models for gastrointestinal mucosal protection, tendon and ligament healing, wound repair, and vascular biology. The 2025 systematic review¹³ by Vasireddi, Hahamyan, Salata, and colleagues in HSS Journal synthesized 36 studies (35 preclinical, 1 retrospective human study) and found that all controlled efficacy work remains in animal models, with no completed controlled human trials published. Research interest centers on its proposed anti-inflammatory, pro-angiogenic, and connective tissue repair mechanisms.

What is the difference between BPC-157 and TB-500?

TB-500 is a synthetic fragment of thymosin beta-4, a protein involved in actin regulation and cell migration. BPC-157 is a synthetic fragment derived from human gastric juice protein. The two compounds have different sequences, different proposed mechanisms, and different research backgrounds. Both are unapproved for human use, both appear on the WADA Prohibited List¹⁴ (BPC-157 under S0, Non-Approved Substances, and TB-500 under S2, Peptide Hormones, Growth Factors, Related Substances, and Mimetics), and neither has completed controlled human efficacy trials. They are sometimes discussed together in recovery and sports contexts, but they are distinct compounds with distinct pharmacological profiles.

What does WADA's ban on BPC-157 mean for athletes?

Under the 2026 WADA Prohibited List¹⁴, BPC-157 is prohibited at all times under Section S0 (Non-Approved Substances). An athlete who tests positive for BPC-157 faces an anti-doping rule violation, as with any other prohibited substance. Athletes subject to anti-doping testing should regard any product containing or potentially contaminated with BPC-157 as a prohibited substance.

Is BPC-157 the same as a compounded medication?

No. A compounded medication under section 503A is a preparation made by a state-licensed pharmacist or physician using only bulk ingredients the law allows⁶: ones with a USP monograph, ones in an FDA-approved drug, or ones on FDA's 503A bulks list. BPC-157 is not on the 503A bulks list or in Category 1, so no pathway currently covers its use in compounding. Products sold as "compounded BPC-157" are not legally compounded medications. They are unregulated products produced outside the pharmaceutical regulatory system.

More for digestive & weight